Workflow
Biotechnology
icon
搜索文档
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
Globenewswire· 2025-09-26 13:00
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy NANTES, France – September 26, 2025, 7:00 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), Inserm Transfert (on behalf of Inserm, a French public organization dedicated to human health), and Nantes University today announce the signing of a strategic partnership agreement aimed at accelerating the development of innovative projects in the fields of immuno ...
Mixed Catalysts Drive After-Hours Moves In MRM, LEXX, SHOT, AQST, And OVID
RTTNews· 2025-09-26 11:55
Several small-cap names posted sharp gains in Thursday's after-hours session, driven by fresh corporate updates, clinical developments, and strategic pivots. Below are five stocks that stood out for their notable post-close moves and underlying catalysts.Shares of MEDIROM Healthcare Technologies Inc. (MRM) surged dramatically in after-hours trading on Thursday, climbing 282.8% to $5.55 as of 11:41 PM EDT. The sharp spike followed news that the company will double the installation of its biometric authentic ...
ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
Globenewswire· 2025-09-26 05:43
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized ...
SOLENO INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
Globenewswire· 2025-09-26 05:10
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Soleno and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognize ...
Medicenna Announces Results of Annual Meeting of Shareholders
Globenewswire· 2025-09-26 05:00
TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the voting results from the Company’s annual meeting of shareholders held today, September 25, 2025 (the “Meeting”). Medicenna is pleased to announce that all nominees listed in the management information circular dated August 13, 2025 (the “Circular”), were elected as di ...
GeoVax Labs (NasdaqCM:GOVX) 2025 Conference Transcript
2025-09-26 04:57
GeoVax Labs (NasdaqCM:GOVX) 2025 Conference September 25, 2025 03:55 PM ET Company ParticipantsDavid Dodd - Chairman, President & CEONoneWelcome back. We have an update from GeoVax Labs. Trades on the NASDAQ under GeoVax. It's a clinical-stage biotech company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers. So happy to welcome back Chairman, President, and CEO David A. Dodd. David, welcome back.David DoddThank you, Anna. Today what ...
Organogenesis Provides Update on Second Phase 3 ReNu® Study
Globenewswire· 2025-09-26 04:50
Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpointStatistically significant maintenance of function (p<0.0001)Company will request pre-BLA meeting with FDA to discuss submission pathway CANTON, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the ...
KBR, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - KBR
Prnewswire· 2025-09-26 04:48
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. KBR was aware that the Department of Defense had ongoing concerns about its HomeSafe joint venture, specifically about its ability to fulfill its obligations related to the relocation of armed forces services members and their families. Despite knowing about these concerns, the Company claimed to investors that its performance would continue to grow. Based on these facts, KBR's public statements were fa ...
Quanex Building Products Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NX
Prnewswire· 2025-09-26 04:47
Accessibility StatementSkip Navigation Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. LOS ANGELES, Sept. 25, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Quanex Building Products Corporation ("Quanex " or "the Company") (NYSE: NX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t ...
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR
Prnewswire· 2025-09-26 04:46
Accessibility StatementSkip Navigation LOS ANGELES, Sept. 25, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. ("Jasper" or "the Company") (NASDAQ: JSPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible l ...